Literature DB >> 31225634

Echocardiographic assessment of tricuspid regurgitation and pericardial effusion after cardiac device implantation.

Katarzyna Wiechecka1, Bartosz Wiechecki1, Agnieszka Kapłon-Cieślicka2, Agata Tymińska1, Monika Budnik1, Dominika Hołowaty1, Krzysztof Jakubowski1, Marcin Michalak1, Elżbieta Świętoń1, Przemysław Stolarz1, Roman Steckiewicz1, Marcin Grabowski1, Piotr Scisło1, Janusz Kochanowski1, Krzysztof J Filipiak1, Grzegorz Opolski1.   

Abstract

BACKGROUND: The frequency of cardiac implantable electronic device (CIED) implantations is constantly increasing. Pericardial effusion (PE) and tricuspid regurgitation (TR) may occur after CIED implantation. The aim of the present study is to evaluate the prevalence and risk factors for new occurrences or progression of TR and PE early after CIED implantation.
METHODS: This is an on-going, single-center, observational study of patients after their first CIED implantation, with an echocardiographic evaluation within 60 days before and 7 days after the procedure. Data are presented for first 110 consecutive patients who underwent CIED implantation from August 2015 to July 2016.
RESULTS: Median age was 75 years, and 44% were women. In total, 87 (79%) pacemakers, 21 (19%) implantable cardioverter-defibrillators and 2 cardiac resynchronization therapy devices were implanted. After CIED implantation, there was TR progression in 17 (16%) patients: 5 patients developed moderate TR, none developed severe TR. An increase in TR was more often observed after implantations performed by operators in training than by certified operators (35% vs. 12%, p = 0.02). New PE after the procedure was observed in 8 (7%) patients and was trivial ( < 5 mm) in all cases. Patients with new PE after implantation had lower baseline hemoglobin levels and tended to be women.
CONCLUSIONS: New PE and an increase in TR severity are rare complications early after CIED implantation. Operator experience might be related to TR progression. Increasing the number of patients in the current on-going study will allow a more reliable assessment of the prevalence and risk factors of these complications.

Entities:  

Keywords:  cardiac implantable electronic device; complications; implantable cardioverter- -defibrillator; pacemaker

Year:  2019        PMID: 31225634      PMCID: PMC8079086          DOI: 10.5603/CJ.a2019.0053

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  29 in total

1.  Permanent pacemaker lead entrapment: role of the transesophageal echocardiography.

Authors:  Jean Champagne; Paul Poirier; Jean G Dumesnil; Denis Desaulniers; J R Boudreault; Gilles O'Hara; Marcel Gilbert; François Philippon
Journal:  Pacing Clin Electrophysiol       Date:  2002-07       Impact factor: 1.976

Review 2.  Interventional cardiology perspective of functional tricuspid regurgitation.

Authors:  Shikhar Agarwal; E Murat Tuzcu; E Rene Rodriguez; Carmela D Tan; L Leonordo Rodriguez; Samir R Kapadia
Journal:  Circ Cardiovasc Interv       Date:  2009-12       Impact factor: 6.546

3.  Increased prevalence of significant tricuspid regurgitation in patients with transvenous pacemakers leads.

Authors:  D Paniagua; H R Aldrich; E H Lieberman; G A Lamas; A S Agatston
Journal:  Am J Cardiol       Date:  1998-11-01       Impact factor: 2.778

Review 4.  Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation - Messages from the 2018 EHRA.

Authors:  Anna Tomaszuk-Kazberuk; Lukasz Kołtowski; Paweł Balsam; Marek Koziński; Agnieszka Kapłon-Cieślicka; Karolina Kupczyńska; Justyna Domienik-Karłowicz; Anna Budaj-Fidecka; Piotr Buszman; Maciej Wybraniec; Paweł Burchardt; Błażej Michalski; Miłosz J Jaguszewski
Journal:  Cardiol J       Date:  2018       Impact factor: 2.737

5.  Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up.

Authors:  Ulas Höke; Dominique Auger; Joep Thijssen; Ron Wolterbeek; Enno T van der Velde; Eduard R Holman; Martin J Schalij; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan
Journal:  Heart       Date:  2014-01-21       Impact factor: 5.994

6.  Perforation of the tricuspid valve by a transvenous pacemaker.

Authors:  L Gould; C V Reddy; U Yacob; M Teich; A DeMartino; D DePalma; R F Gomprecht
Journal:  JAMA       Date:  1974-10-07       Impact factor: 56.272

7.  Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

Authors:  J P Singh; J C Evans; D Levy; M G Larson; L A Freed; D L Fuller; B Lehman; E J Benjamin
Journal:  Am J Cardiol       Date:  1999-03-15       Impact factor: 2.778

Review 8.  Tricuspid regurgitation in patients with pacemakers and implantable cardiac defibrillators: a comprehensive review.

Authors:  Rasha Al-Bawardy; Amar Krishnaswamy; Mandeep Bhargava; Justin Dunn; Oussama Wazni; E Murat Tuzcu; William Stewart; Samir R Kapadia
Journal:  Clin Cardiol       Date:  2013-03-25       Impact factor: 2.882

9.  Transesophageal echocardiographic evaluation of tricuspid valve regurgitation during pacemaker and implantable cardioverter defibrillator lead extraction.

Authors:  Simone Roeffel; Frank Bracke; Albert Meijer; Berry Van Gelder; Jan Melle Van Dantzig; Cees Joost Botman; Kathinka Peels
Journal:  Pacing Clin Electrophysiol       Date:  2002-11       Impact factor: 1.976

10.  Tricuspid incompetence following permanent pacemaker implantation.

Authors:  Marc Klutstein; Jonathan Balkin; Adi Butnaru; Michael Ilan; Amnon Lahad; David Rosenmann
Journal:  Pacing Clin Electrophysiol       Date:  2009-03       Impact factor: 1.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.